Emergent Awarded NIAID Contract That Increases Potential Funding To Over $58 Million For Advanced Development Of Third Generation Anthrax Vaccine
Source: Medical News Today
Friday 3rd September, 2010
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $28.7 million with the National Institute of Allergy and Infectious Diseases (NIAID), an institute w... ...
Read the full story at
Medical News Today
Email this story to a friend
Have your say on this story
